ABBV · 10-Q · 2026Q3 · Full report
Outstanding Indebtedness
AbbVie Inc. · 2026-11-03 · Importance 64 · Surprise 42 · In source text
AbbVie issued $18.0 billion aggregate principal of unsecured senior notes during the nine months ended September 30, 2026, and repaid $2.0 billion of a 364-day term loan and $2.0 billion of 3.20% senior notes. The company had no commercial-paper borrowings at September 30, 2026, compared with $499 million outstanding at December 31, 2025. Its $5.0 billion revolving facility matures in March 2028 and its $3.0 billion facility matures in January 2030; neither facility had borrowings outstanding at September 30, 2026. AbbVie terminated its $10.0 billion 364-day term loan facility in August 2026 after issuing senior notes, and Moody’s upgraded its senior unsecured rating to A2 in February 2026.
Key facts
- In July 2026, AbbVie entered into a $10.0 billion 364-day senior unsecured term loan facility in connection with the Apogee acquisition and terminated it in August 2026 after issuing $10.0 billion of senior notes. source
- AbbVie had revolving credit facilities of $5.0 billion maturing in March 2028 and $3.0 billion maturing in January 2030; no amounts were outstanding under them at September 30, 2026 or December 31, 2025. source
- AbbVie issued $18.0 billion aggregate principal of unsecured senior notes in the nine months ended September 30, 2026. source
- AbbVie repaid $2.0 billion aggregate principal of its 364-day term loan credit agreement and $2.0 billion aggregate principal of 3.20% senior notes during the nine months ended September 30, 2026. source
- In February 2026, Moody’s upgraded AbbVie’s senior unsecured long-term credit rating to A2 from A3 and its short-term rating to Prime-1 from Prime-2. source
- In June 2026, S&P affirmed AbbVie’s A- senior unsecured long-term credit rating and revised its outlook to positive from stable. source
- AbbVie disclosed that adverse changes to its credit ratings could negatively affect future financing arrangements, although they would not prevent drawing on its credit facility or accelerate scheduled debt maturities. source
- AbbVie had no commercial-paper borrowings outstanding at September 30, 2026, compared with $499 million outstanding at December 31, 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | realized | -12.2% | AbbVie issued $18.0 billion aggregate principal of unsecured senior notes in the nine months ended September 30, 2026. |
| cash | positive | realized | +12.2% | AbbVie issued $18.0 billion aggregate principal of unsecured senior notes in the nine months ended September 30, 2026. |
| liability | positive | realized | +2.7% | AbbVie repaid $2.0 billion aggregate principal of its 364-day term loan credit agreement and $2.0 billion aggregate principal of 3.20%… |
| cash | negative | realized | -2.7% | AbbVie repaid $2.0 billion aggregate principal of its 364-day term loan credit agreement and $2.0 billion aggregate principal of 3.20%… |